The adoption of risk-based monitoring (RBM) strategies has grown rapidly over the last decade. In fact, one study reported more than 40% growth of RBM in new trial starts from 2016 to 2018. Despite this, and the FDA’s guidance supporting the implementation of new RBM approaches, the industry has been slow to fully embrace RBM’s benefits.
As a result, we’re missing the opportunity to save huge amounts of time and money.
In this white paper, we will discuss:
- The benefits of a sound RBM strategy
- Potential reasons why the industry has been slow to adopt
- How to choose the right technologies to support your objectives